The Zhitong Finance App learned that Rongchang Biotech (09995) rose more than 4% in the intraday period. As of press release, it had risen 3.45% to HK$27, with a turnover of HK$18.193,500.
According to the news, on June 13, Rongchang Biotech announced that verdicitumab (trade name: Edison) achieved positive results in phase III clinical treatment of HER2-positive advanced breast cancer patients with liver metastases, reaching the end of the main study. The company plans to submit a marketing application to the Drug Evaluation Center (CDE) of the State Drug Administration in the near future. According to reports, in 2023, Rongchang Biotech's sales volume of injectable verdicitumab was 173,700 units, an increase of 15.24% over the previous year.